EXHIBIT 13.1
To the Shareholders of
Commonwealth Biotechnologies, Inc.
CBI's focus in 2000 was in three major areas: the drive towards profitability,
redefinition of its mission and enhancement of its technological services.
Profitability
Revenues exceeded expenses in the first and second quarters of 2000 for the
first time since CBI's initial public offering in 1997, reversing the status
quo of revenues chasing expenses. Although gains were lost in the last two
quarters of 2000, the Company still completed its fiscal year operations on or
exceeding budget in almost all categories. Revenues were up 71% over 1999 while
expenses rose a modest 13%. Revenues exceeded $4.3 million for the first time
ever as CBI signed several long-term contracts.
In 2001, the Company's focus will continue to be on profitability. CBI is a
successful contract research organization (CRO), generating revenues which in
turn, permit the development and funding of intellectual properties. This
year's success is attributable to watchful management and CBI's ability to
attract long-term contractual clients who utilize all aspects of the Company's
technology base. This ability stems from CBI's state-of-the-art expertise and
instrumentation, recognized leadership in the field and aggressive marketing.
Profitability was also realized from implementation of new sources of revenue,
such as paternity testing, genomics, proteomics and microbiology.
Mission: Concept-to-Clinic
Concept-to-Clinic is the key to CBI's continued success. It defines the
approach taken with all clients--design, development, implementation and
testing. Whether the client is a start-up Company with research and development
needs, or an established firm wishing to move a product through clinical
regulation, CBI stands ready as partner of choice to provide the required
services that ensure success. You are encouraged to read more about this
successful approach on the ensuing pages. The use of Concept-to-Clinic is
evidenced in the broad array of services CBI offers its clients.
1
Technological Services
Contractual Research
CBI's growth is attributed in part to its focus on signing long-term
contractual clients. For example, two long-term clients have signed continuing
contracts for 2001. CBI continues to serve as subcontractor to the Illinois
Institute of Technology Research Institute (IITRI) for proprietary protocol
development work. This contract was valued at over $1.4 million for 2000 and is
expected to bring nearly $8 million to the Company over its five-year term. CBI
is the prime contractor for a second sponsor, which focuses on research aimed
at identifying novel molecules. This contract is valued at about $1 million for
a one-year period. These contracts represent unique opportunities for CBI in
that the work involves nearly every employee at the Company and involves
virtually every technology.
CBI must develop new technologies to service these and other contracts. New
technologies are expected to bring additional revenue to the Company when they
are commercialized. In addition to contractual research, in the past year
several technology platforms have produced notable results at CBI. In the
coming year still other platforms promise to play equally exciting roles in
CBI's growth. Some of these technologies are discussed below.
Paternity Testing
There has been a dramatic and constant increase in the number of private
paternity cases implemented at CBI. The Company routinely processes upwards of
125 inquiries per month. This workload generated nearly a 1000% increase in
revenue compared to 1999. CBI is recognized worldwide for its expertise in this
area. The Company routinely receives samples from the Pacific Rim countries for
analysis as a result of service agreements it has with Korean and Japanese
companies. In 2000, CBI received accreditation from the American Association of
Blood Banks and renewed its accreditation with the National Forensic Science
Technology Council.
Genotyping Services
CBI implemented rapid and novel techniques for genotyping analysis in 2000 that
have been applied to cell culture lines. Consequently, the Company performs
identity and lineage analysis on different cell lines for various clients.
Total revenue derived from genotyping services alone increased 1000% compared
to 1999. CBI anticipates these techniques to continue to positively impact
profitability in the future.
2
Drug Development
CBI implemented Drug Development as a new technology platform in January 2001.
This technology complements its current inventory of services and allows CBI to
offer complete development of potential human pharmaceuticals, from conception
through pre-clinical trials and onto early phase clinical trials (I and II).
Drug Development is a primary focus for CBI's new Concept-to-Clinic mission and
marketing approach. To launch this service, the Company initially sought to
acquire a small firm that specializes in the field. CBI then negotiated to
simply acquire this firm's existing contracts. The Company also retained key
expert personnel. CBI is now fully operational in Drug Development
capabilities, and is currently identifying new clients and contracts.
Genome Services
In 2000, CBI implemented a state-of-the-art genomics platform. The services CBI
offers include DNA genome-scale sequence determination, real time PCR analysis,
array technologies and bioinformatics processes. CBI began a collaborative
project to sequence the genome of the microbial pathogen Streptococcus Sanguis
under the auspices of a federally funded grant from the National Institutes of
Health.
Proteomics
CBI has already acquired the instrumentation necessary to become a center for
proteomic study (The proteome is the spectrum of proteins produced by an
organism). Proteomics is the principle end target of genomic analysis, where
function is ascribed to proteins, which are revealed through genomic sequence
determination. With publication of the human as well as other organisms'
genetic road map, proteomics will rapidly become the leading technology
platform leading to new drugs for human diseases. Having a proteomics platform
positions CBI to assist clients who wish to capitalize on the wealth of DNA
sequence information in the public domain. CBI has integrated molecular
modeling, bioorganic synthesis, over-expression and protein purification
services within its proteomic platform.
3
2000 Highlights
CBI garnered its share of recognition in 2000.
January CBI was highlighted by the Richmond Times Dispatch for its large and
diverse client list, its global client base, its existing contracts and its
patents.
February CBI announced a joint alliance with november AG of Erlangen, Germany.
Together, CBI and november are developing novel technologies for analysis of
environmental analytes that it believes will provide a platform technology for
commercialization in the coming years. The alliance with november also opens
CBI to European markets. Orders for peptides and other materials have recently
been realized through this alliance. February also brought news about
AccuTrac(TM), a reagent CBI developed that facilitates automated DNA sequence
analysis. CBI received "Notice of Allowance of All Claims" from the US Patent
Office, and the US patent for AccuTrac(TM) issued in August.
March CBI announced its entry into genomics and proteomics research. In August
the Company announced a genomics analysis contract to determine the genetic
blueprint for Streptococcus Sanguis, a major contributor to dental caries and a
leading cause of human heart valve and blood infections. In the proteomics
field, CBI is conducting research into several clinically and environmentally
relevant bacteria.
April CBI announced its second joint alliance for 2000 with Vigen Laboratories,
Inc., of Wilmette, IL. In conjunction with Vigen, CBI has developed (and has
filed the appropriate patent applications) real-time PCR detection methods for
the presence of the HIV virus and of four members of the herpes virus family.
With this technology platform in place, CBI is now advertising its capabilities
to screen patient samples for these viruses and to perform high throughput
screening of potential anti-viral compounds. CBI has already realized its first
revenues from analysis of patient sera. With the approval and support of Vigen,
CBI's Drug Development group will move the assay platform through the FDA
validation process. In April, CBI also announced record revenues for the first
quarter of 2000 and, for the first time since its1997 IPO, a net profit to the
Company.
August CBI was recognized by Deloitte and Touche for its "Virginia Technology
Fast 50" designation. CBI was later recognized as a Deloitte and Touche
"National Fast 500" awardee. Over the previous five-year period, CBI's revenues
grew by more than 650% to gain this national recognition. August also brought
the announcement that CBI had doubled its sales compared with the same period
last year and realized a profit for the first six months of the fiscal year.
CBI also announced a joint alliance with Kemp Biotechnologies. Kemp offers
large-scale (1000L) over-expression services, which are not offered by CBI.
Kemp utilizes CBI for its pilot scale, molecular biology and protein analytical
services.
September CBI successfully closed a private placement of stock. The proceeds of
this transaction are being used to enhance CBI's marketing efforts, to purchase
needed equipment, to implement Drug Development as a platform technology and to
subsidize general operating expenses. CBI was highlighted as a leading public
CRO in the September issue of R & D Directions.
November The US Patent Office issued CBI a "Notice of Allowance of All Claims"
for its "Continuation in Part" to the US patent for HepArrest(TM), the
Company's lead human pharmaceutical product. With commercialization as its
goal, CBI is currently engaged in discussions with other potential licensing
partners for further development of HepArrest(TM). CBI is also actively
exploring other avenues for commercialization. Various companies have exhibited
strong interest in HepArrest(TM).
4
Under strict restrictions of use, CBI has supplied several firms with samples
for experiments in their own labs. Success with these experiments will likely
facilitate an acceptable agreement structure for CBI's commercialization of
HepArrest(TM). CBI also announced a joint alliance with Richter International
in November. Together, CBI and Richter will develop and implement state-of-the-
art food microbiology analysis services.
December George Allen resigned from the Board of Directors of CBI to accept his
new position as US Senator in Washington, DC. Senator Allen has been a valued
contributor to the growth and direction of CBI, and the Company thanks him for
his efforts on its behalf. Moving forward, CBI announced appointment of three
new board members who will stand for affirmation at the 2001 Annual Meeting of
Shareholders. Dr. Donald McAfee is Chairman and Chief Technical Officer of
Discovery Therapeutics, Inc. of Richmond, VA, and has over 30 years experience
in biomedical research. He has been responsible for moving four novel drug
candidates from the bench to clinical trials and has successfully negotiated
numerous licensing agreements with multinational strategic partners. Mr. Samuel
P. Sears, Jr. is a nationally known attorney who specializes in legal
management and negotiation of mergers and acquisitions. Mr. Sears is currently
acting as consultant to two biotech start-up firms. Mr. Everette G. ("Buddy")
Allen, Jr. is chairman and senior partner in the law firm of Hirschler,
Fleischer, Weinberg, Cox and Allen, PC of Richmond, VA. He concentrates his
practice in litigation, commercial disputes, finance and debt restructuring.
The Management of CBI welcomes these new board members and looks forward with
anticipation to their help in growing CBI.
Thank You for Your Continued Support
CBI is ready for the new millennium. To all its hard-working employees, CBI
again owes its thanks and gratitude. To the Company's current Board of
Directors, its consultants, many clients and vendors, and especially to its
shareholders, CBI again says thanks.
With best regards,
/s/ Richard J. Freer
- --------------------------------
Richard J. Freer, Ph.D.,
Chairman of the Board
/s/ Robert B. Harris
- --------------------------------
Robert B. Harris, Ph.D.,
President
/s/ Thomas R. Reynolds
- --------------------------------
/s/ Thomas R. Reynolds,
Senior Vice President,
Secretary
/s/ James H. Brennan
- --------------------------------
James H. Brennan
Controller
CBI welcomes your calls and inquiries.
Phone: 800-735-9224
- --------------------------------------------------------------------------------
Fax: 804-648-2642
- --------------------------------------------------------------------------------
E-Mail: info@cbi-biotech.com
- --------------------------------------------------------------------------------
Web: www.cbi-biotech.com
- --------------------------------------------------------------------------------
Address: 601 Biotech Drive
Richmond, VA 23235
- --------------------------------------------------------------------------------
You are cordially invited to attend CBI's 2001 Annual Meeting of Shareholders
on May 7, 2001 at 11:00 a.m. at the Company's facility.
5
CBI's Foundation
The mainstay of CBI continues to be its platform technology business. In 2000,
CBI was again able to successfully recruit qualified scientists to join its
staff, in part because of their interest in developing cutting-edge
technologies. The outcome of these efforts is technology commercialization,
which contributes greatly to CBI's recognition as one of the most comprehensive
contract research organizations in life sciences research anywhere in the
world. CBI offers custom synthetic organic and bioorganic chemistries,
spectroscopy services and a full complement of protein, DNA/RNA, and genetic
identity and analysis testing services. At any given moment, CBI routinely has
numerous contract proposals pending with various potential clients with a
combined total valuation of several million dollars. CBI now boasts over 1900
clients in over 850 institutions worldwide.
All CBI's technologies are fully detailed in its promotional brochures and on
its Web page. The Company is now equipped with fax-on-demand services for
potential customers who want CBI's literature (1-877-329-4224). More than 60%
of all inquiries and more than 50% of all orders CBI receives come via the
Internet.
CBI's CRO Clients
CBI's clients are from private companies, academic institutions and government
agencies across the globe. Virtually all CBI's clients are engaged in life
sciences research. They use CBI's technologies to provide data and results to
support their individual research programs. As of December 2000 nearly 80% of
CBI's clients were from private companies. CBI adds about 20 new clients per
month.
CBI has made a conscious effort to redefine its client base. Through its
aggressive marketing efforts, CBI has successfully changed its image from a
"menu" driven Company (where a client might order one or two analyses) to a
"project oriented" Company (where a client contracts with CBI to move a project
from conception to practice). In the evolution of CBI's business and as prices
and technologies changed, it became increasingly clear to the Company that it
would be very difficult to sustain business if CBI had to rely on investigators
who provided individual samples for analysis. It was simply not economically
viable to consider nurturing growth on the basis of orders for individual
analyses or individual orders for a limited DNA sequencing project. The only
answer was large-scale, solution-oriented, one-stop shopping.
Concept-to-Clinic at Work
Many of CBI's long-term clients are entrepreneurs with an idea or a patent who
have no laboratory facilities to speak of. These clients contract with CBI to
help further develop their ideas in silico (on the computer), to do the basic
research necessary to prove the concept and, finally, to reduce the idea to
practice--Concept-to-Clinic. In one example, CBI undertook a project with a
biotech start-up Company to isolate, purify, characterize and develop methods
of analysis of a putative marker for malignant (cancerous) cells and tumors.
Armed with nothing more than some passing literature references, CBI scientists
have now isolated the target molecule and have developed two different immuno
assays to measure both the target molecule and antibodies in human plasma
against the target molecule. The work has progressed to the stage where the FDA
is currently reviewing the immuno assay tests for clinical acceptance. CBI was
remunerated for all aspects of the development work and is compensated for
performance of the immuno assays on a per-test basis. Ongoing work includes
detailed characterization of the molecular target. Clearly, the potential
market for early cancer detection is unlimited.
Also consider CBI's joint alliance with Vigen, another example of successful
Concept-to-Clinic. CBI was initially contracted to isolate and then
characterize the putative anti-viral bioactive component of interest to Vigen.
In the course of the work, it became clear that a rapid, reproducible and
reliable method of assay was required which would replace the three-week cell
culture assay method that was previously used by other investigators
6
under contract to Vigen. To meet this challenge, CBI scientists first developed
a TaqMan(TM) real-time PCR (polymerase chain reaction) assay to detect HIV
viral DNA and then--in rapid succession--performed all the bioinformatics,
design, synthesis and developmental work necessary to implement TaqMan(TM)
assays for different herpes viruses. CBI has filed patents to protect these
properties. Together, Vigen and CBI are commercializing these screening
platforms.
Concept-to-Clinic also affects those CBI clients who have enormous in-house
research and development capabilities but who seek to outsource much of this
work for technical, strategic, or economic reasons. Simply put, CBI possesses
the expertise and instrumentation necessary to develop a project to its
potential, which makes it economically feasible for a major Company to
outsource its work to CBI. Many of CBI's clients are multinational companies.
Under contract, CBI has helped them develop new product lines, or has
implemented new methods of quality control for them, or has simply performed
sophisticated macromolecular analyses on their behalf.
Continued Growth with an Eye Towards Profitability
CBI's business strategy is sound. It is the Company's intent to continue to
provide its clients with comprehensive, integrated technology platforms, and to
allow its clients to use CBI's services for all their outsource needs. However,
CBI is not complacent in its current position. CBI constantly seeks new areas
for growth and development--areas that can be implemented at minimal cost for
maximum revenue return.
In 2001, CBI will increase its marketing efforts by enhancing its Web page and
creating hot links to its strategic partners. CBI will advertise more in
professional journals. Each advertisement has been designed to have maximum
impact. The Company's trade show booth is being revamped. CBI will display its
capabilities at selected trade shows throughout the year, where prospective
clients and opportunities abound.
CBI will continue to focus on acquiring long-term contractual clients.
Management is writing a higher number of larger-volume, higher-dollar proposals
than ever before. The Company is capitalizing on its recognized expertise in
mass spectrometric methods, DNA sequence analysis, molecular biology, and other
vital research areas. CBI is now uniquely positioned to compete as a prime
contractor for government-sponsored projects and routinely responds to RFPs
(requests for proposals) from different government agencies.
CBI continues to create and implement new platform technologies. In addition to
the TaqMan(TM) services already described, CBI and Richter International will
develop state-of-the-art food microbiological assay procedures. Such methods
are essential to guarantee the safety of the nation's food supply, especially
with regard to US military stationed overseas in strategically important areas
of the world.
In 2001, CBI will expand its Drug Development capabilities. CBI now has the
ability to submit IND (investigational new drug) applications on behalf of
biotechnology start-up firms and to coordinate and supervise Phase I and Phase
II clinical trials of potential new human pharmaceuticals. With the successful
start of this technology platform, CBI now truly represents "one-stop
biotechnology shopping." Not only will CBI be able to develop a biotech
product, but also will help move the product through early stages of the
complex regulatory process.
CBI already has a proven track record in competing for extramural funding for
its intellectual properties. In 2001 CBI intends to exploit this mechanism for
identifying funds that will be used to develop new product lines, as well as to
help develop new platform technologies.
CBI is committed to growing its paternity, genotyping and CODIS data base
revenue streams. CBI is accredited by the American Association of Blood Banks
(AABB) and by the National Forensics Science Technology Council (NFSTC). The
Company is also accredited under the Clinical Laboratories Investigations Act
(CLIA). These accreditations allow CBI to perform paternity
7
testing, genetic analysis and to submit DNA sequence information ("DNA
fingerprints") to the FBI national database.
CBI has several expansion efforts planned for 2001. The Company will
inaugurate at-home paternity test kits, expand its marketing for paternity
testing beyond the Internet and regional Yellow Pages, continue to compete
aggressively for CODIS databasing contracts and continue to automate its
laboratory procedures in these areas. The AABB estimates that nearly 800,000
paternity tests will be conducted in the US during 2001. Of these, nearly
50,000 cases will be private. CBI is well positioned to capture a significant
portion of this market.
Proprietary Research and Development
CBI has developed its own intellectual properties that promise to add a sig-
nificant revenue stream to the Company when they are fully commercialized.
HepArrest(TM)
HepArrest(TM) is intended for use in acute surgical situations where the anti-
coagulant effects of Heparin must be reversed. When surgery is concluded, res-
toration of clotting function is critical to prevent unwanted bleeding and re-
lated post-operative complications. CBI has completed virtually all pre-clini-
cal laboratory studies necessary to file its own IND for HepArrest(TM). With
implementation of its Drug Development platform, CBI is positioned to move
HepArrest(TM) through the regulatory compliance process. Concom itantly, the
Company is seeking a licensing partner who will complete the IND and clinical
trial process on its behalf. United States patents have been issued for
HepArrest(TM). National patent filings for the product are pending in Europe,
Canada and Japan, the three largest potential markets for HepArrest(TM) out-
side of the United States. At present, HepArrest(TM) has few other viable com-
petitors. Even if a new product were to be developed shortly, HepArrest(TM) is
considerably further along in the commercialization process. If HepArrest(TM)
comes to market and continues to perform in clinical trials as it has in pre-
clinical trials, it is not unimaginable that HepArrest(TM) could capture a
significantly higher market share than 65%.
AccuTrac(TM)
In August 2000 the US patent for AccuTrac(TM) was issued to CBI. AccuTrac(TM)
is a laboratory reagent, which facilitates the process of automated DNA se-
quence analysis. CBI is selling AccuTrac(TM) worldwide and under non-exclusive
license through Cosmo Bio Co., Ltd. of Tokyo, Japan. The Company is currently
negotiating additional non-exclusive license agreements while continuing to
market and directly sell the reagent.
Focus on Profitability
CBI management has outlined a logical and progressive program to realize prof-
itability throughout 2001. Much depends on CBI's ability to close new long-
term contracts that are pending with potential clients. However, over the last
two fiscal years, CBI has demonstrated that revenue growth does not have to be
accompanied by proportional increases in expenses. Compared with 1999, revenue
increased 71% while expenses increased a modest 13%. For the most part, CBI
already has the capacity and personnel in place to continue to grow revenues
while only moderately increasing expenses.
8
STOCKHOLDER MATTERS
Market for Common Equity
The Company completed its initial public offering on October 28, 1997 at a
price per share of $6.00. Since that time, the Common Stock has traded on the
NASDAQ Small Cap Market ("NASDAQ"). The following table sets forth the range of
high and low sales price per share of common stock for 2000 and 1999.
- -------------------------------------------------------
2000 1999
- -------------------------------------------------------
High Stock Low Stock High Stock Low Stock
Period Price Price Price Price
- -------------------------------------------------------
1st Quarter, $30.000 $7.625 $ 9.250 $7.875
- -------------------------------------------------------
2nd Quarter, $12.125 $7.000 $ 9.000 $6.438
- -------------------------------------------------------
3rd Quarter, $ 9.875 $5.750 $ 6.563 $4.188
- -------------------------------------------------------
4th Quarter, $ 9.000 $3.437 $10.250 $4.750
- -------------------------------------------------------
On March 15, 2001 the last reported sales price for a share of the Company's
Common Stock on NASDAQ was $ 4.06. As of March 1, 2001, there were 761 holders
of record of the Company's Common Stock and approximately 881 beneficial
holders.
The Company has not paid any cash dividends on its Common Stock. The Company
intends to retain its earnings to finance the growth and development of its
business and does not expect to declare or pay dividends in the foreseeable
future. The declaration of dividends is within the discretion of the Company.
However, the Company's ability to pay dividends is constrained by certain
provisions of its industrial revenue bond financing.
Selected Financial Data
Set forth below is selected
financial data with respect
to the Company for the
years ended December 31,
2000 and December 31, 1999,
which has been derived from
the audited financial
statements of the Company.
The selected financial data
set forth below should be
read in conjunction with
"Management's Discussion
and Analysis of Financial
Conditions and Results of
Operations."
Management's Discussion and
Analysis of Financial
Condition and Results of
Operations
The following should be
read in conjunction with
"Selected Financial Data"
and the Company's Audited
Financial Statements and
Notes thereto included
herein.
- ------------------------------------------------------------------------------
For the years Ended
- ------------------------------------------------------------------------------
December 31, 2000 December 31, 1999 December 31, 1998
- ------------------------------------------------------------------------------
Operational Data:
- ------------------------------------------------------------------------------
Revenues: $ 4,366,959 $2,565,132 $ 1,604,267
- ------------------------------------------------------------------------------
Net Loss <921,916> <2,091,194> <2,096,937>
- ------------------------------------------------------------------------------
Loss per common share $ <0.51> $<1.27> $<1.29>
- ------------------------------------------------------------------------------
Weighted average common
shares outstanding 1,807,142 1,641,738 1,622,340
- ------------------------------------------------------------------------------
Balance Sheet Data:
- ------------------------------------------------------------------------------
Total Current Assets $ 2,469,882 $ 560,576 $ 2,471,022
- ------------------------------------------------------------------------------
Total Assets $10,343,694 $8,250,369 $10,401,182
- ------------------------------------------------------------------------------
Total Current
Liabilities $ 916,743 $ 967,866 $ 1,114,563
- ------------------------------------------------------------------------------
Total Liabilities $ 4,994,129 $4,967,866 $ 5,114,563
- ------------------------------------------------------------------------------
Total Stockholders
equity $ 5,349,565 $3,282,503 $ 5,286,619
- ------------------------------------------------------------------------------
9
Business Considerations
In October 1997, the Company closed its initial public offering (IPO) and
received net proceeds of $5,417,578, net of underwriting and other costs. In
connection with the IPO, the underwriters purchased warrants for 101,500
shares of common stock. The warrants are exercisable for a period of five
years at an exercise price of $9.90 per share.
Since 1997 and through 2000, the Company incurred recurring operating losses
due to increased operating costs without corresponding increases in revenues.
Through 2000, these deficits were substantially funded through use of funds
obtained from the private placement and IPO. The Company has also used
proceeds from its offerings for capital acquisitions, which were primarily
funded through its issuance of Industrial Revenue Development Bonds.
At December 31, 1999, the Company had used virtually all of the funds received
in connection with its offerings. The following highlights describe
significant factors that have occurred in 2000 with respect to continued
operations:
. During the quarter ended March 31, 2000, approximately $575,000 in funds was
received from the exercise of stock options. In addition, management
anticipates that, if the stock price remains strong, additional capital will
be received in 2000 from the exercise of management and underwriter
warrants.
. On September 27, 2000, the Company completed a private placement of common
stock and warrants to purchase common stock and received net proceeds of
$2,350,397. The proceeds were used to pay off the line of credit and for
additional general working capital needs.
. In the fourth quarter of 1999, the Company was awarded a five-year annually
renewable subcontract valued at $8.5 million with the Illinois Institute of
Technology Research Institute. During the third quarter of 2000, the second
year of this contract was awarded to the Company and is expected to provide
revenues of approximately $1.2 million. This revenue will be recognized
during the fourth quarter of 2000 and the first three quarters of 2001.
. At December 31,2000, the Company has approximately thirty-six contracts out
for bid with various potential customers. These contracts, if awarded,
would provide the Company with approximately $7.4 million to $12.7 million
in revenues over the next two to three years.
. The Company continues to seek a pharmaceutical partner to begin clinical
trials with regulatory bodies and to market HepArrest(TM) worldwide.
. Management continues to monitor and reduce operating costs.
Overview
The Company's revenues are derived principally from providing macromolecular
synthetic and analytical services to researchers in the biotechnology industry
or who are engaged in life sciences research in government or academic labs
throughout the world. Development of innovative technologies for biotechnology
requires sophisticated laboratory techniques and the Company provides these
services to customers on a contract basis. The Company's customers consist of
private companies, academic institutions and government agencies, all of which
use biological processes to develop products for health care, agricultural,
and other purposes.
The Company generally derives revenue from two types of customers: those who
require a discrete set of services ("short-term projects"), and those who
contract with the Company on an extended basis for performance of a variety of
integrated services ("long-term projects"). More often than not, the Company's
customers provide
repeat business to the Company. Historically, a majority of the Company's
revenues have been earned under short-term projects. However, the Company
views long-term projects as the more important source of revenue, and has
continued to focus its efforts on identifying long-term customers. Long-term
projects generally range from a few months to more than a year. Revenues are
generally recognized as services are rendered or as products are
10
delivered. In addition, revenue is also recognized with performance-based
installments payable over the contract duration as milestones are achieved.
The Company also derives revenues from government grants that partially fund
the Company's research efforts for its proprietary technologies. All government
grants are expense reimbursement grants which provide for reimbursement on a
monthly basis of the Company's direct costs incurred in a research project,
plus indirect costs stated as a percentage of direct costs.
The Company realized a net loss for the years ended December 31, 2000 and
December 31,1999 of $921,916 and $2,091,194, respectively. These results are
consistent with the Company's business plan for 2000. The loss in 2000 has
improved over the loss in 1999 due to an increase of $1,677,801 in revenues
from contract research. This improvement reflects management's continuing
efforts to identify and obtain long-term contracts.
Effective January 1, 2001, the Company announced that it has purchased the
current contracts and the rights to pending contracts of the Drug Development
Group of SRA Life Sciences, Inc., (SRA) Falls Church, VA. SRA's Drug
Development Group's core staff, including its Director of Drug Development, has
joined CBI to support ongoing and future projects. These individuals will
continue to operate from Falls Church, VA. Drug development comprises
consulting, management, and implementation of all services required to move a
client's drug, process, or device candidate through its research and
development phase, pre-clinical laboratory studies, clinical trials, and
regulatory phases of the regulatory approval process. This acquisition
completes the continuum of services required to support a client's product or
process from its conceptualization through its presentation to regulatory
agencies for final pre-market approval. The Company will begin a very
aggressive marketing effort to reach not only new clients but also to raise the
awareness of our current client base, many of which have products in their
pipelines which could benefit from this new capability. The Company's intention
is to target small to
medium biotech companies seeking to commercialize their products but which
don't have in-house regulatory expertise.
Results of Operations
Year Ended December 31, 2000 Compared to Year Ended December 31, 1999
Revenues
The Company experiences fluctuations in all revenue categories. Continuation of
existing projects, or engagement for future projects is usually dependent upon
the customer's satisfaction with the scientific results provided in initial
phases of the scientific program. Continuation of existing projects or
engagement of future projects also often depends upon factors beyond the
Company's control, such as the timing of product development and
commercialization programs of the Company's customers. The combined impact of
commencement and termination of research contracts from several large customers
and unpredictable fluctuations in revenue for laboratory services can result in
very large fluctuations in financial performance.
Gross revenues increased by $1,801,827 or 70.2% from $2,565,132 during the year
ended December 31, 1999 to $4,366,959 during the year ended December 31, 2000.
Revenues realized from laboratory services increased by $257,054, or 28.8% from
$892,652 during 1999 to $1,149,706 during 2000. This increase is primarily due
to the startup of Paternity testing. Revenues realized from this activity have
amounted to $284,846 during 2000 compared to $30,410 in 1999.
Revenues realized from contract research increased by $1,677,801 or 115.1%,
from $1,457,310 during 1999 to $3,135,111 during 2000. Of the total revenue
from contract research, one major customer represents 52.2% of the revenue
earned during the period. This project was awarded from the Illinois Institute
of Technology Research Institute (see "Business Considerations"). During the
third quarter of 2000, the second year of this contract was
11
awarded to the Company and is expected to provide revenues of $1.2 million.
This revenue will be recognized during the fourth quarter of 2000 and the first
three-quarters of 2001.
The Company experienced a decrease in revenue realized from government grants
in the amount of $104,522, or 60.2%, from $173,750 during 1999 to $69,228
during 2000. This decrease is primarily due to the completion of all of the
grants in house. The elimination of government grants is consistent with the
Company's business plan for 2000 to devote its efforts on identifying long-term
customers.
The Company experienced a decrease in revenue realized from AccuTrac in the
amount of $28,506, or 68.8%, from $41,420 during 1999 to $12,914 during 2000.
This decrease is primarily due to purchases in 1999 after the initiation of the
product into the market, which was not continued in 2000.
Expenses
Cost of Services. Cost of services consists primarily of labor, laboratory
supplies and miscellaneous indirect costs. The cost of services increased by
$1,008,381, or 60.2%, from $1,675,677 during 1999 to $2,684,058 during 2000.
The cost of services as a percentage of revenue was 61.5% and 65.3% during 2000
and 1999, respectively.
Labor costs increased by $761,222, or 97.9%, from $777,320 during 1999 to
$1,538,542 during 2000. This increase reflects a reallocation of the Company's
resources to the general operations of the business from the research and
development and General and Administrative areas. This reallocation is
necessary to support the additional long-term projects currently in progress.
The costs for direct materials increased by $154,943, or 20.1%, from $770,544
during 1999 to $925,487 during 2000. These increased costs are directly
attributable to the increase in revenues. Other costs increased by $92,216, or
72.1%, from $127,813 during 1999 to $220,029 during 2000. This increase in
costs is due to increases in additional postage, maintenance and repairs of
equipment and lease expenditures on equipment.
Selling, General and Administrative. Sales, general and administrative expenses
("SGA") consist primarily of compensation and related costs for administrative,
marketing and sales personnel, facility expenditures, professional fees,
consulting, taxes, and depreciation. Total SGA costs decreased by $204,984, or
8.6%, from $2,371,608 during 1999 to $2,166,624 during 2000. As a percentage of
revenue, these costs were 49.6% and 92.5% during 2000 and 1999, respectively.
Total Compensation and Benefits decreased by $259,300 or 40.0% from $648,094
during 1999 to $388,794 during 2000. This decrease is primarily attributable to
the reallocation of personnel in the administrative area to work on the
subcontract from the Illinois Institute of Technology Research Institute.
Professional and consulting fees increased by $70,873, or 26.7%, from $265,777
during 1999 to $336,650 during 2000. This increase is primarily due to the
additional expenditures in business and Directors and Officers liability
insurance. In addition, increased legal fees associated with management's
proposed acquisition of SRA Life Sciences, Inc. and the defending of its
AccuTrac patent also contributed to this increase.
Depreciation increased by $46,560, or 8.8%, from $530,412 during 1999 to
$576,972 during 2000. This increase is primarily due to the purchases of new
equipment during the year.
Office expenses increased by $34,889, or 34.7%, from $100,491 during 1999 to
$135,380 during 2000. This increase is primarily due to additional operating
and office supplies needed to support the operations of the Company.
Marketing costs decreased by $171,316 or 58.5%, from $292,662 during 1999 to
$121,346 during 2000. Reductions in advertising, public relations and payments
for consulting services contributed to the decrease in marketing costs.
12
Sales costs decreased by $47,982 or 62.4%, from $76,860 during 1999 to $28,878
during 2000. Elimination of the sales department contributed to the decrease in
costs.
Other costs increased by $137,111 or 152.5%, from $89,889 during 1999 to
$227,000 during 2000. This increase is primarily due to the bad debt written-
off from one customer in the amount of $122,553.
Research and Development. Research and development costs within the Company
fall into two general categories: grant-related research and development and
in-house research and development. These categories are distinguished by those
performed in support of government grant-sponsored programs, and those
performed in the absence of such grants which are funded from working capital.
Total expenditures for these two categories decreased by $230,211, or 60.6%,
from $379,753 during 1999 to $149,542 during 2000. Total grant-related research
and in-house research as a percentage of revenue was 3.4% and 14.8% during 2000
and 1999, respectively.
Expenditures to perform grant-related research activities decreased by $113,472
or 61.6%, from $184,293 during 1999 to $70,821 during 2000. This decrease is
primarily due to the completion of all of the grants in house.
Expenditures made by the Company for in-house research activities decreased by
$116,740 or 59.7%, from $195,461 during 1999 to $78,721 during 2000. This
decrease is primarily attributable to the reallocation of personnel in the
research and development area to work on the subcontract from the Illinois
Institute of Technology Research Institute.
Other Income (Expenses)
Interest income to the Company decreased by $14,339, or 18.2% from $78,993
during 1999 to $64,654 during 2000. Interest income has been derived from
investing the unused portion of the funds realized by the Company from the
successful sale (March 1998) of Industrial Revenue Bonds (IRBs) for
construction of the Company's new facility. Interest income on this segment
decreased due to the reduction in funds used for the completion of the project.
Interest costs incurred by the Company during 1999 and 2000 included (1)
interest paid to financial institutions for loans made to the Company; 2)
interest paid for the Company's IRBs; 3) amortization of costs incurred as a
consequence of the completion of the Company's IRB financing; and 4) interest
costs associated with the line of credit from a significant stockholder of the
Company, which included the valuation of options issued in connection
therewith. Interest expense increased by $45,024 or 14.6% from $308,281 during
1999 to $353,305 during 2000.
Year Ended December 31, 1999 Compared to Year Ended December 31, 1998
Revenues
Gross revenues increased by $960,865 or 59.9% from $1,604,267 during the year
ended December 31, 1998 to $2,565,132 during the year ended December 31,1999.
The Company experiences fluctuations in all revenue categories. Continuation of
existing projects, or engagement for future projects is usually dependent upon
the customer's satisfaction with the scientific results provided in initial
phases of the scientific program. Continuation of existing projects or
engagement of future projects also often depends upon factors beyond the
Company's control, such as the timing of product development and
commercialization programs of the Company's customers. The Company is unable to
predict for more than a few months in advance the volume and dollar amount of
future projects. The combined impact of commencement and termination of
research contracts from several large customers and unpredictable fluctuations
in revenue for laboratory services can result in very large fluctuations in
financial performance.
13
Short Term Projects
Revenues realized from short-term projects which is included in the Statement
of Operations as Laboratory Services, increased by $16,144, or 1.8%, from
$876,508 during 1998 to $892,652 during 1999.
Revenues realized from peptide synthesis increased by $33,601 or 18.2% from
$184,632 during 1998 to $218,233 during 1999. Revenues attributable to protein
sequencing increased by $44,869 or 36.4%, from $123,385 during 1998 to $168,254
during 1999. Revenues derived from peptide synthesis and protein sequencing
increased primarily due to
new customers placing orders with the Company. Revenues realized from molecular
biology increased by $15,408 or 154.7% from $9,957 during 1998 to $25,365
during 1999. Revenues from the new core technologies, Genetic Analysis,
reported revenues during 1999 of $30,410. Revenues from DNA Sequencing
decreased by $169,986 or 44.7% from $380,575 during 1998 to $210,589 during
1999. This decrease is primarily due to a change in the marketplace wherein
most DNA sequence activities are becoming associated with long-term projects.
Other "uncategorized" revenues increased by $15,410 or 17.9% from $86,327
during 1998 to $101,737 during 1999. This increase is primarily due to
additional work from our customers not previously done in prior years. These
classifications are usually one-time events. Revenues realized from other core
technologies remained essentially constant.
Long Term Projects
Revenues realized from various long-term projects, which is included in the
Statement of Operations as Contract Research, increased by $990,855, or 212.4%,
from $466,455 during 1998 to $1,457,310 during 1999.
This increase is primarily due to work being done on twenty-seven individual
projects during 1999 compared to only fourteen projects during 1998. Of the
twenty-seven projects initiated during the year, two customers accounted for
28.3% and 20.2% of the long-term contract revenue base, respectively. The
Company's management continues to take an active role in negotiating new
contracts. However, management is unable to say with certainty when or whether
additional long-term contracts will be awarded.
Research Grants
The Company experienced a decrease in revenue realized from government grants
in the amount of $87,554, or 33.5%, from $261,304 during 1998 to $173,750
during 1999. This decrease is primarily due to completion of two of the three
grants. Those grants were the Phase II Small Business Technology Research grant
(SBTR) from the National Institutes of Health (NIH) and a Phase I SBIR award
from the NIH for development of Rapid Assay Methods for the Detection of
Botulism. The remaining grant, a ($200,000) Phase II Small Business Innovative
Research Award (SBIR) from the United States Department of Agriculture (USDA)
for development of a Diagnostic for Equine Infectious Anemia Infection has
begun its second year. Remaining funds left total $82,839. The Company
anticipates completion of the project by August 2000.
AccuTrac(TM) Revenue
The Company began sales of a new reagent (AccuTrac(TM)) which facilitates the
process of automated DNA sequence analysis. Revenues during 1999 amounted to
$41,420. There were no sales during 1998.
In February, 2000, CBI was notified of allowance of its claims on its United
States patent application for its product, AccuTrac(TM), a reagent which
facilitates the process of automated DNA sequence analysis. CBI is selling
AccuTrac worldwide and just recently, we signed a non-exclusive agreement with
Cosmo Bio Co., Ltd., Tokyo, Japan for distribution of AccuTrac in Japan. Cosmo
Bio Co., Ltd, is one of the leading distributors of chemical and biological
reagents in Japan and as part of our agreement, Cosmo Bio Co., Ltd., will mount
an aggressive marketing campaign for AccuTrac which will target investigators
involved in DNA sequencing projects in
14
Japanese companies and research institutions. A second distribution agreement
with a second Japanese Company is pending.
Expenses
Cost of services consists primarily of labor and laboratory supplies. The cost
of services increased by $550,113, or 48.9%, from $1,125,564 during 1998 to
$1,675,677 during 1999. The cost of services as a percentage of revenue was
70.2% and 65.3% during 1998 and 1999, respectively.
Direct Materials
The costs for direct materials increased by $242,575, or 45.9%, from $527,969
during 1998 to $770,544 during 1999. Increases in direct materials were
twofold. First, increases, by our suppliers, in purchases of reagents,
chemicals and miscellaneous materials used in all the laboratories. Second,
additional work being done on twenty-seven individual projects during 1999
compared to only fourteen projects during 1998. Of the twenty-seven projects
initiated, one customer accounted for 18.7% of the material costs during 1999.
Direct Labor
Labor costs increased by $265,656, or 51.9%, from $511,664 during 1998 to
$777,320 during 1999. This increase reflects a reallocation of the Company's
resources to the general operations of the business from the research and
development area. In addition, due to the increase in long-term contracts,
personnel assigned to Selling, General and Administrative (SG&A), performed
additional responsibilities in the laboratories.
Other Costs
Other costs (postage, travel, equipment rental, maintenance of equipment, etc)
increased by $41,882 or 48.7% from $85,931 during 1998 to $127,813 during 1999.
This increase was due to the repairs and maintenance on equipment of $28,861.
Other increases included, waste removal of $14,289, subcontracting services of
$9,729, and freight delivery to the Company's clients of $16,304.
Selling,General and Administrative
Sales, general and administrative expenses ("SGA") consist primarily of
compensation and related costs for administrative, marketing and sales
personnel, facility expenditures, professional fees, consulting, taxes, and
depreciation. Total SGA costs decreased by $126,993, or 5.7%, from $2,244,615
during 1998 to $2,371,608 during 1999. As a percentage of revenue, these costs
were 139.9% and 92.5% during 1998 and 1999, respectively.
Compensation and Benefits
Total Compensation and Benefits decreased by $134,739 or 17.2% from $782,833
during 1998 to $648,094 during 1999. This decrease is primarily attributable to
the resignation of one of the Company's executive officers, who opted to return
to his former academic position. Additional reductions are due to reassigning a
portion of management salaries allocated to direct labor and research and
development.
Facility Costs
Costs for facilities decreased by $24,283, or 10.0%, from $241,845 during 1998
to $217,562 during 1999. This decrease is primarily due to the elimination of
leased laboratory costs associated with the relocation of the Company to its
new corporate headquarters. Additional costs associated with the relocation and
new to the Company include electricity of $110,620, gas utility bills of
$15,501, water usage of $4,388, and janitorial services of $9,035. Other
facility costs include increases in telephone use of $35,307, facility
maintenance costs of $7,259, and association fees of $9,511.
Professional Services
Professional fees increased by $65,610 or 32.8%, from $200,167 during 1998 to
$265,777 during 1999. This increase was primarily due to legal and accounting
costs associated with the year-end audit, quarterly accounting reviews, general
legal support, legal costs associated with obtaining patents, and corporate
liability insurance costs.
15
Taxes and Licenses
Taxes and License fees increased by $66,773 or 152.3% from $43,835 during 1998
to $110,608 during 1999. This increase is primarily due to an increase in
personal property taxes paid to the new jurisdiction in which the facility is
located. In addition, initial expenditures for Virginia sales tax and real
estate taxes associated with the new facility were realized during 1999.
Depreciation Expense
Depreciation increased by $220,479 or 71.1% from $309,933 during 1998 to
$530,412 during 1999. Increased depreciation costs are attributable to the
purchase of additional laboratory equipment consistent with expanding the
Company's technology base, and the twelve months of depreciation on the
Company's new corporate facility. There were no depreciation costs during 1998
for any facility costs associated by the Company.
Marketing
Marketing costs decreased by $60,100 or 17.0%, from $352,762 during 1998 to
$292,662 during 1999. Reduction in the use of non-Company professional media
relations work and the elimination of attendance at several trade show costs
contributed to the decline in expenditures.
In September, 1998, the Company entered into a contract with the Mattson Jack
Group to perform a global market assessment of the Company's potential human
therapeutic, HepArrest(TM). Total costs during 1998 amounted to $101,083
compared to $66,667 during 1999.
Research and Development
Research and development costs within the Company fall into two general
categories: grant-related research and development and in-house research and
development. These categories are distinguished in the Company by those
performed in support of government grant-sponsored programs, and those
performed in the absence of such grants and funded from working capital. Total
expenditures for these two categories decreased by $95,245, or 20.1%, from
$474,998 during 1998 to $379,753 during 1999. Total grant-related research and
in-house research as a percentage of revenue were 29.6% and 14.8% during 1998
and 1999, respectively.
Grant-Related Research Activities
Expenditures to perform grant-related research activities decreased by $18,666,
or 9.2%, from $202,957 during 1998 to $184,293 during 1999. All of the
Company's grant related expenditure are reimbursed from the appropriate
governmental agency. This decrease in costs is primarily due to two of the
three grants being completed during 1999.
Grants completed during 1999 included, a Phase II Small Business Technology
Research grant (SBTR) grant from the National Institutes of Health (NIH).
Expenses incurred through 1999 amounted to $82,356 and a Phase I SBIR award
from the NIH for development of Rapid Assay Methods for the Detection of
Botulism. Expenditures incurred through 1999 amounted to $32,455. The remaining
grant, a ($200,000) Phase II Small Business Innovative Research Award (SBIR)
from the United States Deparmeent of Agriculture (USDA), is for the development
of a Diagnostic for Equine Infectious Anemia Infection. Expenses incurred
through 1999 amounted to $70,084. The Company anticipates completion of the
project by August 2000.
In-House Research Activities
Expenditures made by the Company for in-house research activities decreased by
$76,580 or 28.2%, from $272,041 during 1998 to $195,461 during 1999. This
decrease is primarily due to the reallocating of salaries from research and
development to direct labor. This reallocation was necessary to support the
additional long-term projects initiated by the Company. However, the Company
continues to be actively engaged in establishing fundamental methods for
genetic testing for agricultural and human applications, in developing methods
of genome sequence analysis, and in pursuing fundamental research related to
potential uses of
16
HepArrest in drug formulation. In addition the Company is continuing its in-
house research and development efforts with AccuTrac(TM).
Other Income and Expenses
Interest income (in total) to the Company decreased by $249,634, or 76.0% from
$328,627 during 1998 to $78,993 during 1999.
Interest income to the Company derived during 1998 resulted from investing the
unused portion of the funds realized by the Company from the private placement
of convertible notes in June 1997. These funds decreased by $208,636, or 86.9%
from $240,096 during 1998 to $31,460 during 1999.
Interest income to the Company was also derived during 1998 from investing the
unused portion of the funds-realized by the Company from the successful sale
(March, 1998) of Industrial Revenue Bonds (IRBs) for construction of the
Company's new facility. These funds decreased by $67,977 or 76.8% from $88,532
during 1998 to $20,555 during 1999.
Interest costs incurred by the Company during the 1999 and 1998 included (1)
interest paid to financial institutions as loans made to the Company; (2)
interest paid for the Company's IRBs; and (3) amortization of costs incurred as
a consequence of the completion of the Company's IRB financing. Total interest
expense and amortization increased by $123,626 or 66.9% from $184,655 during
1998 to $308,281 during 1999. This increase is primarily due the payment of
twelve months interest for the Company's IRBs during 1999 as compared to nine
months and fifteen days during 1998.
Liquidity and Capital Resources
For the year ended 2000, the Company reflected a decrease in cash of $558,229
from operating activities, as compared to a decrease of $2,072,244 from
operating activities during the 1999 year. The cash outflow in 2000 was
primarily due to the continuation of investments made by the Company in
facility costs, personnel, equipment, sales, and marketing efforts. The cost
outlays in 2000 were made possible by capital realized in the fourth quarter
from the private placement of common stock and warrants to purchase common
stock. Net proceeds received amounted to $2,350,397. The cost outlays in 1999
were made possible by capital realized from the Company's private placement of
convertible notes and initial public offering of public stock.
Net working capital (deficit) as of December 31, 2000 and December 31, 1999 was
$1,553,139 and ($407,290) respectively. This improvement is a direct result of
record revenues for the Company, significant cost cutting measures adopted by
management, and the private placement of common stock and warrants to purchase
common stock. The proceeds of the private placement were used to pay off the
line of credit and for general working capital needs.
The Company continues to search for long-term projects as the more important
source of revenue and has continued to focus its efforts on identifying long-
term customers. Long-term projects generally range from a few months to more
than a year. In the fourth quarter of 1999, the Company was awarded a five-year
subcontract with the Illinois Institute of Technology Research Institute. The
contract is valued at approximately $8.5 million and has provided approximately
$1.1 million in gross cash flow for the 2000. During the third quarter of 2000,
the second year of this contract was awarded to the Company and is expected to
provide revenues of approximately $1.2 million.
At December 31, 2000, the Company has approximately thirty-six contracts out
for bid with various potential customers. These contracts, if awarded, would
provide the Company with approximately $7.4 million to $12.7 million in
revenues over the next two to three years.
17
Forward Looking Statements
Management has included herein certain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended. When used, statements
that are not historical in nature, including the words "anticipated",
"estimate", "should", "expect", "believe", "intend", and similar expressions
are intended to identify forward-looking statements. Such statements are, by
their nature, subject to certain risks and uncertainties.
Among the factors that could cause the actual results to differ materially from
those projected are the following:
. business conditions and the general economy,
. the development and implementation of the Company's long-term business goals,
. federal, state, and local regulatory environment,
. lack of demand for the Company's services,
. the ability of the Company's customers to perform services similar to those
offered by the Company "in-house,"
. potential cost containment by the Company's customers resulting in fewer
research and development projects,
. the Company's ability to receive accreditation to provide various services,
including, but not limited to paternity testing, and
. the Company's ability to hire and retain highly skilled employees.
Other risks, uncertainties, and factors that could cause actual results to
differ materially from those projected are detailed from time to time in
reports filed by the company with the Securities and Exchange Commission,
including Forms 8-K, 10-QSB, and 10-KSB.
18
[LOGO OF MCGLADREY & PULLEN, LLP] RSM
-------------
international
Independent Auditor's Report
To the Board of Directors and Stockholders
Commonwealth Biotechnologies, Inc.
Richmond, Virginia
We have audited the accompanying balance sheets of Commonwealth
Biotechnologies, Inc. as of December 31, 2000 and 1999 and the related
statements of operations, changes in stockholders' equity, and cash flows for
the years then ended. These financial statements are the responsibility of the
Company's management. Our responsibility is to express an opinion on these
financial statements based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards in the United States of America. Those standards require that we plan
and perform the audit to obtain reasonable assurance about whether the
financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in
the financial statements. An audit also includes assessing the accounting
principles used and significant estimates made by management, as well as
evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in
all material respects, the financial position of Commonwealth Biotechnologies,
Inc. as of December 31, 2000 and 1999, and the results of its operations and
its cash flows for the years then ended, in conformity with accounting
principles generally accepted in the United States of America.
/s/ McGladrey & Pullen, LLP
Richmond, Virginia
February 9, 2001
19
Commonwealth Biotechnologies, Inc.
BALANCE SHEETS
December 31, 2000 and 1999
- -------------------------------------------------------------------------------
2000 1999
- -------------------------------------------------------------------------------
Assets
Current Assets
Cash and cash equivalents $ 587,156 $ 31,630
Accounts receivable (Notes 4 and 8) 792,071 458,677
Investments (Note 2) 995,789 --
Prepaid expenses and other current assets 94,866 70,269
- -------------------------------------------------------------------------------
Total current assets 2,469,882 560,576
- -------------------------------------------------------------------------------
Property and Equipment, net (Notes 3, 4 and 5) 7,153,852 7,019,109
- -------------------------------------------------------------------------------
Other Assets
Bond issuance costs, less accumulated amortization
2000 $29,905; 1999 $19,161 238,693 249,437
Restricted cash (Note 5) 445,020 418,047
Contract acquisition costs (Note 6) 33,047 --
Deposits and other 3,200 3,200
- -------------------------------------------------------------------------------
Total other assets 719,960 670,684
- -------------------------------------------------------------------------------
$ 10,343,694 $ 8,250,369
- -------------------------------------------------------------------------------
Liabilities and Stockholders' Equity
Current Liabilities
Demand note payable (Note 4) $ 134,680 $ 199,680
Line of credit (Notes 4 and 13) -- 282,000
Current maturities of long-term debt (Note 5) 207,431 --
Accounts payable and other current liabilities 548,914 480,726
Deferred revenue 25,718 5,460
- -------------------------------------------------------------------------------
Total current liabilities 916,743 967,866
- -------------------------------------------------------------------------------
Long-term debt, less current maturities (Note 5) 4,077,386 4,000,000
- -------------------------------------------------------------------------------
Total liabilities 4,994,129 4,967,866
- -------------------------------------------------------------------------------
Commitments and contingencies (Notes 6 and 7)
Stockholders' Equity (Notes 11, 12 and 13)
Common stock, no par value, 10,000,000 shares
authorized, 2000 2,076,164; 1999 1,643,727, shares
issued and outstanding -- --
Additional paid-in capital 11,905,864 8,925,742
Accumulated deficit (6,565,155) (5,643,239)
Accumulated other comprehensive income (Note 2) 8,856 --
- -------------------------------------------------------------------------------
Total stockholders' equity 5,349,565 3,282,503
- -------------------------------------------------------------------------------
$ 10,343,694 $ 8,250,369
- -------------------------------------------------------------------------------
See Notes to Financial Statements.
20
Commonwealth Biotechnologies, Inc.
STATEMENTS OF OPERATIONS
Years Ended December 31, 2000 and 1999
- --------------------------------------------------------------------
2000 1999
- --------------------------------------------------------------------
Revenue (Note 8):
Laboratory services $ 1,149,706 $ 892,652
Contract research 3,135,111 1,457,310
Product sales 12,914 41,420
Government grants 69,228 173,750
- --------------------------------------------------------------------
Total revenue 4,366,959 2,565,132
- --------------------------------------------------------------------
Costs and expenses (Note 9):
Cost of services and goods 2,684,058 1,675,677
Sales, general and administrative 2,166,624 2,371,608
Research and development 149,542 379,753
- --------------------------------------------------------------------
Total costs and expenses 5,000,224 4,427,038
- --------------------------------------------------------------------
Operating loss (633,265) (1,861,906)
- --------------------------------------------------------------------
Other income (expense):
Interest expense (Note 4) (353,305) (308,281)
Interest income 64,654 78,993
- --------------------------------------------------------------------
Total other income (expense) (288,651) (229,288)
- --------------------------------------------------------------------
Net loss $ (921,916) $ (2,091,194)
- --------------------------------------------------------------------
Loss per common share, basic and diluted $ (0.51) $ (1.27)
- --------------------------------------------------------------------
STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
Years Ended December 31, 2000 and 1999
- -----------------------------------------------------------------------------------------
Number Additional Other
of Shares Paid-In Accumulated Comprehensive
Outstanding Capital Deficit Income Total
- -----------------------------------------------------------------------------------------
Balance, January 1,
1999 1,633,214 $ 8,838,664 $ (3,552,045) $ -- $ 5,286,619
Issuance of common
stock 10,513 63,078 -- -- 63,078
Fair value of options
issued in connection
with line of credit
(Note 4) -- 24,000 -- -- 24,000
Net loss -- -- (2,091,194) -- (2,091,194)
- -----------------------------------------------------------------------------------------
Balance, December 31,
1999 1,643,727 8,925,742 (5,643,239) -- 3,282,503
Issuance of common
stock, net of shares
surrendered 432,437 2,953,122 -- -- 2,953,122
Fair value of options
issued in connection
with line of credit
(Note 4) -- 27,000 -- -- 27,000
Comprehensive loss: --
Unrealized gain (loss)
on Investments (Note
2) -- -- -- 8,856 8,856
Net loss -- -- (921,916) -- (921,916)
- -----------------------------------------------------------------------------------------
Comprehensive loss -- -- -- -- (913,060)
- -----------------------------------------------------------------------------------------
Balance, December 31,
2000 2,076,164 $ 11,905,864 $ (6,565,155) $ 8,856 $ 5,349,565
- -----------------------------------------------------------------------------------------
See Notes to Financial Statements.
21
Commonwealth Biotechnologies, Inc.
STATEMENTS OF CASH FLOWS
Years Ended December 31, 2000 and 1999
- ----------------------------------------------------------------------------
2000 1999
- ----------------------------------------------------------------------------
Cash Flows From Operating Activities
Net loss $ (921,916) $ (2,091,194)
Adjustments to reconcile net loss to net cash
used in operating activities:
Depreciation and amortization 634,539 547,156
Realized gains on sale of Investments (1,306) --
Changes in assets and liabilities:
Accounts receivable (333,394) (155,741)
Prepaid expenses (24,598) 6,232
Accounts payable 68,188 (316,871)
Deferred revenue 20,258 (61,826)
- ----------------------------------------------------------------------------
Net cash used in operating activities (558,229) (2,072,244)
- ----------------------------------------------------------------------------
Cash Flows From Investing Activities
Contract acquisition costs (33,047) --
Purchases of debt securities, available-for-
sale (1,354,960) --
Sales of debt securities, available-for-sale 367,510 --
Purchases of property and equipment (332,889) (285,734)
- ----------------------------------------------------------------------------
Net cash used in investing activities (1,353,386) (285,734)
- ----------------------------------------------------------------------------
Cash Flows From Financing Activities
Restricted cash (26,973) (15,056)
Principal payments on long-term debt, note
payable and capital lease obligations (159,008) (50,000)
Proceeds from line of credit -- 300,000
Principal payments on line of credit (300,000) --
Proceeds from issuance of common stock 2,953,122 63,078
- ----------------------------------------------------------------------------
Net cash provided by financing activities 2,467,141 298,022
- ----------------------------------------------------------------------------
Net increase (decrease) in cash and cash
equivalents 555,526 (2,059,956)
Cash and cash equivalents:
Beginning 31,630 2,091,586
- ----------------------------------------------------------------------------
Ending $ 587,156 $ 31,630
- ----------------------------------------------------------------------------
Supplemental Disclosures of Cash Flow
Information
Cash payments for interest $ 297,489 $ 291,538
- ----------------------------------------------------------------------------
Supplemental Schedule of Non-Cash Investing and
Financing Activities
Capital lease obligations incurred for use of
equipment $ 378,825 $ --
- ----------------------------------------------------------------------------
See Notes to Financial Statements.
22
COMMONWEALTH BIOTECHNOLOGIES, INC.
Notes to Financial Statements
- --------------------------------------------------------------------------------
Note 1. Nature of Business and Significant Accounting Policies
Nature of business: Commonwealth Biotechnologies, Inc., (the "Company"), was
formed on September 30, 1992, for the purpose of providing specialized
analytical laboratory services for the life scientist. The Company provides
basic research services in the general areas of protein/peptide and DNA/RNA
chemistries. Such services include synthesis, sequence analysis, composition
analysis, protein purification and biophysical characterization of biologically
relevant materials. The Company also pursues its own research and development
leading to intellectual properties.
A summary of the Company's significant accounting policies follows:
Estimates: The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of asset and liabilities and
disclosure of contingent asset and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the period.
Actual results could differ from those estimates.
Revenue recognition: The Company recognizes revenue and related profit upon the
completion of laboratory service projects, or upon the delivery and acceptance
of biologically relevant materials that have been synthesized in accordance
with project terms. Laboratory service projects are generally administered
under fee-for-service contracts or purchase orders. Any revenues from research
and development arrangements, including corporate contracts and research
grants, are recognized pursuant to the terms of the related agreements as work
is performed, or as scientific milestones, if any, are achieved. Amounts
received in advance of the performance of services or acceptance of a
milestone, are recorded as deferred revenue.
Cash and cash equivalents: The Company considers all highly liquid debt
instruments purchased with an original maturity of three months or less to be
cash equivalents. At times, the Company maintains cash balances in excess of
FDIC insured amounts.
Investment in debt securities: Management determines the appropriate
classification of securities at the date individual investment securities are
acquired, and the appropriateness of such classification is reassessed at each
statement of financial condition date. The Company currently has no securities
which are classified as held-to-maturity or trading.
Available-for-sale securities consist of debt securities not classified as
trading or held-to-maturity. Available-for-sale securities are stated at fair
value, and unrealized holding gains and losses, net of the related deferred tax
effect, are reported as a separate component of stockholders' equity.
Premiums and discounts on investments in debt securities are amortized over the
contractual lives of those securities, except for mortgage-backed securities
for which prepayments are probable and predictable which are amortized over the
estimated expected lives of those securities. The method of amortization
results in a constant effective yield on those securities (the interest
method). Interest on debt securities is recognized in income as earned, and
dividends on marketable equity securities are recognized in income when
declared. Realized gains and losses, including losses from declines in value of
specific securities determined by management to be other-than-temporary, are
included in income. Realized gains and losses are determined on the basis of
the average cost of the securities sold.
23
COMMONWEALTH BIOTECHNOLOGIES, INC.
Notes to Financial Statements
- --------------------------------------------------------------------------------
Property and equipment: Property and equipment are recorded at cost.
Depreciation is computed principally by the straight-line method over the
following estimated useful lives providing depreciation and amortization for
financial reporting purposes. The cost of repairs and maintenance is expensed
as incurred. The estimated useful lives of assets are as follows:
Years
- ------------------------------------------------
Buildings 39.5
- ------------------------------------------------
Laboratory and computer equipment 5
- ------------------------------------------------
Furniture and fixtures and office
equipment 7
- ------------------------------------------------
Automobile 5
- ------------------------------------------------
Other assets: Bond issuance costs consist of origination cost associated with
the 1999 bond issue and are being amortized over twenty-five years using the
effective interest method. Amortization expense was $10,743 for the years ended
December 31, 2000 and 1999.
Income taxes: Deferred taxes are provided on a liability method whereby
deferred tax assets are recognized for deductible temporary differences and
deferred tax liabilities are recognized for taxable temporary differences.
Temporary differences are the differences between the reported amounts of
assets and liabilities and their tax bases. Deferred tax assets are reduced by
a valuation allowance when, in the opinion of management, it is more likely
than not that some portion or all of the deferred tax assets will not be
realized. Deferred tax assets and liabilities are adjusted for the effects of
changes in tax laws and rates on the date of enactment.
Research and development: Costs incurred in connection with research and
development activities are expensed as incurred. These consist of direct and
indirect costs associated with specific research and development projects.
Internal research and development cost, which are included in research and
development cost in the statement of operations, were $78,721 and $199,316 for
the years ended December 31, 2000 and 1999, respectively.
Loss per common share: Basic loss per share has been computed on the basis of
the weighted-average number of common shares outstanding. Common shares
issuable upon exercise of the employee stock options (see Note 11) have not
been included in the computation because their inclusion would have had an
antidilutive effect applicable to the net loss. Following is information
regarding the computation of loss per share data for the years ended December
31, 2000 and 1999, respectively.
- -----------------------------------------------------------------------------
2000 1999
- -----------------------------------------------------------------------------
Numerator Denominator Numerator Denominator
- -----------------------------------------------------------------------------
Basic loss per share:
Loss available to
stockholders $ (921,916) $ (2,091,194) $ --
Average shares outstanding -- 1,807,142 -- 1,641,738
Effect of dilutive shares -- -- -- --
Fair value of financial instruments: The Company has determined, based on
available market information and appropriate valuation methodologies, that the
fair value of its financial instruments approximates carrying value. The
carrying amounts of cash and cash equivalents, accounts receivable and accounts
payable approximate fair value due to the short-term maturity of the
instruments. The carrying amount of debt approximates fair value because the
interest rates under the credit agreement are predominantly variable, based on
current market conditions.
24
COMMONWEALTH BIOTECHNOLOGIES, INC.
Notes to Financial Statements
- --------------------------------------------------------------------------------
Note 2. Investment in Debt Securities
The following is a summary of the Company's investment in available-for-sale
securities as of December 31, 2000:
- ---------------------------------------------------------------------
Gross Gross
Amortized Unrealized Unrealized Fair
Cost Gains Losses Value
- ---------------------------------------------------------------------
U.S. government securities $ 986,933 $ 8,856 $ -- $ 995,789
- ---------------------------------------------------------------------
The amortized cost and fair value of debt securities classified as available-
for-sale, by contractual maturity, as of December 31, 2000 are as follows:
- -----------------------------------------------------------
Amortized Fair
Cost Value
- -----------------------------------------------------------
Due within one year $ 174,242 $ 174,727
Due after one year through three years 812,691 821,062
- -----------------------------------------------------------
$ 986,933 $ 995,789
- -----------------------------------------------------------
Note 3. Property and Equipment
Property and equipment consisted of the following:
- ------------------------------------------------------------------------------
2000 1999
- ------------------------------------------------------------------------------
Land $ 403,919 $ 403,919
Building 4,904,666 4,816,507
Laboratory equipment 3,185,797 2,659,965
Furniture, fixtures and office and computer equipment 339,886 242,164
Automobile 24,637 24,637
- ------------------------------------------------------------------------------
8,858,905 8,147,192
Less accumulated depreciation 1,705,053 1,128,083
- ------------------------------------------------------------------------------
$ 7,153,852 $ 7,019,109
- ------------------------------------------------------------------------------
Depreciation expense was $576,972 and $530,412 for the years ended December 31,
2000 and 1999, respectively.
Note 4. Demand Notes Payable and Line of Credit
The Company has a demand note payable with a bank, which bears interest at the
bank's prime rate plus 1% (totaling 10.5% at December 31, 2000). The note has
no stated maturity and is collateralized by a security interest in the
Company's accounts receivable, equipment and intangibles.
In September, 1999, the Company obtained an unsecured line of credit in the
amount of $400,000 from a corporation solely owned by a significant stockholder
of the Company. Interest was payable in cash monthly at a rate of 6%. The line
of credit was due on September 30, 2000, and was repaid from the proceeds of a
private placement of the Company's common stock (see Note 11).
In 1999, and as part of the financing agreement related to the line of credit,
the Company issued an option to purchase 10,000 shares of common stock to the
stockholder. These options were credited to additional paid-in capital at their
fair value at date of issuance with a corresponding reduction in the recorded
amount of the outstanding borrowing. The resulting discount was amortized as an
increase to interest expense over the life of the line of credit. In addition,
as part of the consideration given to this stockholder for the letter of
credit, in 2000 the Company issued options to purchase 21,250 shares of common
stock. The additional options were valued at an amount representing interest
expense of 9% per annum beyond the interest payable in cash. The fair value of
these options has been credited to additional paid-in capital with a
corresponding charge to interest expense.
25
COMMONWEALTH BIOTECHNOLOGIES, INC.
Notes to Financial Statements
- --------------------------------------------------------------------------------
Total interest expense related to the line of credit, including the value of
the options awarded, amounted to $58,315 and $8,918 for the years ended
December 31, 2000 and 1999, respectively.
Note 5. Long-term Debt
- --------------------------------------------------------------------------------
Long-term debt consist of:
2000 1999
- ------------------------------------------------------------------------------
Industrial Revenue Development Bonds Series 1998A
(5.2%-7%), payable in monthly installments of
interest only through March 15, 2000, annual
installments of principal and interest from March
15, 2001 through March 15, 2023, secured by a first
deed of trust on land and building with a carrying
value of $5,001,778 $ 3,670,000 $ 3,670,000
Industrial Revenue Development Bonds Series 1998B,
(8%), payable in monthly installments of interest
only through March 15, 2023 and a final payment of
$330,000 due March 15, 2023, secured by a second
deed of trust on land and building with a carrying
value of $5,001,778 330,000 330,000
Capital lease obligation due in monthly installments
of $8,502 to August, 2003, discounted at a rate of
10.9% 235,145 --
Capital lease obligation due in monthly installments
of $3,814 to February, 2002, discounted at a rate of
11.75% 49,672 --
- ------------------------------------------------------------------------------
4,284,817 4,000,000
Less current maturities 207,431 --
- ------------------------------------------------------------------------------
$ 4,077,386 $ 4,000,000
- ------------------------------------------------------------------------------
The bond agreements require the Company to maintain debt service reserve funds,
which are held by a trustee. Debt service reserve funds are included in the
balance sheets as restricted cash.
Maturities of long-term debt are as follows:
Year Amount
- ----------------------
2001 $ 207,431
2002 187,019
2003 160,367
2004 100,000
2005 105,000
Thereafter 3,525,000
- ----------------------
$4,284,817
- ----------------------
Note 6. Commitments, Contingencies and Subsequent Events
Leases: Total rent expense for all operating leases, including equipment leases
for each of the years ended December 31, 2000 and 1999, was $19,943 and
$27,580, respectively.
In connection with the purchase of the drug development contracts from SRA Life
Sciences, Inc. (see below), the Company has committed to leasing office space
in Falls Church, Virginia for a term of six months for a total of $49,680.
Employment agreements: On June 24, 1997, the Company entered into employment
agreements with its founders. Each of the agreements has a term of five years
with specified base salaries and provide for successive one-year terms. In
addition, except for 1997, the employment agreements provide the Company's
executive officers with annual bonuses
26
COMMONWEALTH BIOTECHNOLOGIES, INC.
Notes to Financial Statements
- --------------------------------------------------------------------------------
equal to, in the aggregate, 15% of the Company's pretax net income for the
preceding fiscal year. For the years ended December 31, 2000 and 1999, there
were no bonuses for the Company's executive officers.
Contract purchase: Subsequent to December 31, 2000, the Company purchased
contracts and rights to pending contracts held by the drug-development group of
SRA Life Sciences, Inc. of Falls Church, Virginia for $150,000. In connection
with this purchase, the Company incurred acquisition costs, during 2000,
totaling $33,047. These costs have been capitalized and will be amortized over
the life of the contracts.
Note 7. Retirement Plan
The Company maintains a 401(k) Plan (the "Plan") which covers substantially all
employees. Under the Plan, employees may elect to defer a portion of their
salary, up to the maximum allowed by law, and the Company will match the
contribution up to 1% of the employee's salary. The Company made contributions
of $3,363 and $8,138 to the Plan in 2000 and 1999, respectively.
Note 8. Major Customers
Revenues for the years ending December 31, 2000 and 1999 include revenues from
the following major customers, together with trade receivables due from those
customers:
- -------------------------------------------------------
Trade
Amount of Revenue Receivable Balance
Year Ended December 31, As of December 31,
2000 1999 2000 1999
- -------------------------------------------------------
Customer A $ 1,637,903 $ 294,613 $ 389,439 $ 238,449
Customer B 269,757 413,059 10,712 --
- -------------------------------------------------------
$ 1,907,660 $ 707,672 $ 400,151 $ 238,449
- -------------------------------------------------------
Note 9. Compensation and Benefit Costs
Compensation and benefit costs are included in the statements of operations as
follows:
- ---------------------------------------------------------------------
2000 1999
- ---------------------------------------------------------------------
Cost of services $ 1,538,542 $ 777,320
Selling, general and administrative expenses 388,974 648,094
Research and development costs 126,903 319,849
- ---------------------------------------------------------------------
$ 2,054,419 $ 1,745,263
- ---------------------------------------------------------------------
Note 10. Income Taxes
The difference between expected income tax benefits and income tax benefits
recorded in the financial statements is explained below:
- ------------------------------------------------------------------------------
2000 1999
- ------------------------------------------------------------------------------
Income taxes (credits) computed at 34% statutory rate $ (313,451) $ (731,918)
Change in valuation allowance 347,296 830,883
Other, primarily state income tax benefit (33,845) (98,965)
- ------------------------------------------------------------------------------
$ -- $ --
- ------------------------------------------------------------------------------
27
COMMONWEALTH BIOTECHNOLOGIES, INC.
Notes to Financial Statements
- --------------------------------------------------------------------------------
The significant components of deferred income tax assets and liabilities as of
December 31 consist of the following:
- --------------------------------------------------------------------------
2000 1999
- --------------------------------------------------------------------------
Deferred tax assets:
Effect of net operating loss $ 2,666,236 $ 2,247,779
Other 75,953 78,984
- --------------------------------------------------------------------------
2,742,189 2,326,763
Deferred tax liabilities:
Tax depreciation in excess of book depreciation 359,451 291,321
- --------------------------------------------------------------------------
Net deferred tax asset before valuation allowance 2,382,738 2,035,442
Less valuation allowance 2,382,738 2,035,442
- --------------------------------------------------------------------------
Net deferred tax asset $ -- $ --
- --------------------------------------------------------------------------
Operating loss carryforwards of approximately $7,024,000 may be used to offset
future taxable income and expire in various years through 2020. The Company
also has research and development credit carryforwards of approximately $50,000
that expire in various years through 2020.
Note 11. Private Placement Offering
On September 27, 2000, the Company completed a private placement of 348,000
shares of common stock at a purchase price of $7.471 per share and warrants to
purchase an additional 348,000 shares of common stock. The warrants are divided
into two equal portions, with one-half having the right to purchase one share
of common stock at a price of $6.50 per share for period of eighteen months,
the other half having the right to purchase one share of common stock at a
purchase price of $6.50 per share for a period of five years. The warrants are
callable at the option of the Company at a price of $10.40 per share. As of
December 31, 2000, no warrants have been exercised. Proceeds, net of issuance
costs, totaled $2,350,397.
Note 12. Stock Compensation
The Company adopted its Stock Incentive Plan (the "Plan") on June 24, 1997. The
Plan provides for the granting to employees, officers, directors, consultants
and certain other nonemployees of the Company of options to purchase shares of
common stock. A maximum of 410,000 shares of common stock may be issued
pursuant to the Plan. Of the maximum number of shares to be issued under the
Plan, 270,000 have been reserved for incentive awards to be granted to the
founders of the Company, and 61,000 shares are reserved for incentive awards to
be granted to others. Additionally, the Company has reserved an aggregate of
201,500 shares of common stock for issuance upon exercise of the Underwriter's
Warrants (100,000) and the Management warrants (101,500).
Incentive awards may be in the form of stock options, restricted stock,
incentive stock or tax offset rights. In the case of incentive stock options
(within the meaning of Section 422 of the Internal Revenue Code of 1986, as
amended), the exercise price will not be less than 100% of the fair market
value of shares covered at the time of the grant, or 110% for incentive stock
options granted to persons who own more than 10% of the Company's voting stock.
Options granted under the Plan generally vest over a five-year period from the
date of grant and are exercisable for ten years, except that the term may not
exceed five years for incentive stock options granted to persons who own more
than 10% of the Company's outstanding common stock.
The Company applies Accounting Principles Board Opinion No. 25 and related
accounting interpretations in accounting for its plan and for management
warrants and, accordingly, no compensation cost has been recognized. Had
compensation cost for the Company's plan been determined based on the fair
value at the grant dates for awards under the plan
28
COMMONWEALTH BIOTECHNOLOGIES, INC.
Notes to Financial Statements
- --------------------------------------------------------------------------------
consistent with the method prescribed by FASB No. 123, Accounting for Stock-
Based Compensation, the Company's net loss and loss per share would have
increased to the proforma amounts indicated below:
- -----------------------------------------------------
2000 1999
- -----------------------------------------------------
Net loss:
As reported, historically $ (921,916) $ (2,091,194)
Proforma (1,026,620) (2,185,093)
Loss per common share:
As reported, historically (0.51) (1.27)
Proforma (0.57) (1.33)
Under FASB No. 123, the fair value of each management stock option and warrant
is estimated on the date of grant using the Black-Scholes option pricing model.
The following weighted-average assumptions were used for grants in 2000 and
1999, respectively: No dividend yield, expected volatility of 122% and 76%,
risk-free interest rate of 5.1% and 6.5%, and expected lives of 5 years.
Stock option transactions are summarized as follows:
- -------------------------------------------------------------------------------
Weighted Weighted
Average Average
Exercise Exercise
2000 Price 1999 Price
- -------------------------------------------------------------------------------
Options and warrants outstanding,
beginning of year 527,287 $ 8.83 531,750 $ 9.11
Granted 86,344 5.64 18,750 5.31
Exercised (92,318) 8.48 (10,513) 6.00
Lapsed (5,600) 8.25 (12,700) 6.43
- -------------------------------------------------------------------------------
Options and warrants outstanding, end of
year 515,713 $ 7.93 527,287 $ 8.83
- -------------------------------------------------------------------------------
Options and warrants exercisable, end of
year 446,560 $ 8.69 402,340 $ 9.11
- -------------------------------------------------------------------------------
Weighted-average fair value per option
and warrant
for options and warrants granted during
the year $ 4.89 $ 3.66
- -------------------------------------------------------------------------------
The following table summarizes information about stock options and warrants
outstanding at December 31, 2000:
- -------------------------------------------------------------------------------
Outstanding Exercisable
- -------------------------------------------------------------------------------
Weighted Weighted Weighted
Average Average Average
Remaining Exercise Exercise
Exercise Contractual Price Price
Prices Number Life Per Number Per
Per Share Outstanding (Years) Share Exercisable Share
- -------------------------------------------------------------------------------
$ 3.75 - 5.25 74,794 5 $ 4.40 66,267 $ 4.40
$ 5.50 - 7.00 47,663 7 5.92 37,513 5.99
$ 7.50 - 9.00 29,500 8 6.78 14,980 7.83
$ 9.25 - 10.00 362,806 5 9.89 327,300 9.90
$ 19.00 - 20.00 950 5 19.93 500 19.88
$ 3.75 - 20.00 515,713 $ 7.93 446,560 $ 8.69
- -------------------------------------------------------------------------------
In addition to the above summary, during 2000, the Company committed to issue
options to purchase 41,750 shares of common stock, which have measurement dates
during the year ended December 31, 2001.
29
COMMONWEALTH BIOTECHNOLOGIES, INC.
Notes to Financial Statements
- --------------------------------------------------------------------------------
Note 13. Business Considerations
In June 1997, the Company sold 60 convertible subordinated notes, with a
principal amount of $50,000, in a private placement offering at an offering
price of $50,000 per note. Each note was automatically converted into a minimum
of 8,333.33 shares of the Company's stock at the closing of the Company's
initial public offering ("IPO"). The Company received net proceeds of
$2,626,269, net of underwriting and other offering costs.
Upon closing of the private placement offering, the Company issued warrants to
members of management for the purchase of 100,000 shares of common stock. The
warrants are exercisable for a period of ten years at an exercise price of
$9.90 per share.
In October 1997, the Company closed its IPO and received net proceeds of
$5,417,578, net of underwriting and other costs. In connection with the IPO,
the underwriters purchased warrants for 101,500 shares of common stock. The
warrants are exercisable for a period of five years at an exercise price of
$9.90 per share.
Since 1997 and through 2000, the Company has incurred recurring operating
losses due to increased operating costs without corresponding increases in
revenues. Through 1999, these deficits were substantially funded through use of
funds obtained from the private placement and IPO. The Company has also used
proceeds from its offerings for capital acquisitions, which were primarily
funded through its issuance of Industrial Revenue Development Bonds. On
September 27, 2000, the Company completed a private placement of 348,000 shares
of common stock and warrants that provided net proceeds of $2,350,397 (see Note
11). The proceeds received from this private placement were used to pay off the
line of credit and to fund general working capital needs.
The Company's financial position has improved from prior years and management
believes that the Company will be able to generate positive net cash flows from
new and existing contracts and by continued monitoring and reduction of
operating costs.
30
(LOGO)
The Executive Officers and Board of Directors
Executive Officers
Richard J. Freer, Ph.D. Robert B. Harris, Ph.D.
Chairman of the Board President
Thomas R. Reynolds James H. Brennan, MBA
Senior Vice President and Secretary
Controller
Directors
Richard J. Freer, Ph.D. Robert B. Harris, Ph.D.
Chairman of the Board President
Thomas R. Reynolds Dr. Raymond Cypess
Vice President and Secretary President and CEO
American Type Culture Collection
L. McCarthy Downs III
Chairman of the Board The Honorable George F. Allen
Anderson & Strudwick, Inc. Director, and Partner
McGuire, Woods, Battle and Booth, LLP
Directors as of 2001
Richard J. Freer, Ph.D. Robert B. Harris, Ph.D.
Chairman of the Board President
Thomas R. Reynolds Dr. Raymond Cypess
Vice President and Secretary President and CEO
American Type Culture Collection
L. McCarthy Downs III
Chairman of the Board Dr. Donald McAfee
Anderson & Strudwick, Inc. Chairman and CTO
Discovery Therapeutics
Samuel P. Sears, Jr.
Attorney at Law Mr. Everette G. Allen, Jr.
Chairman, Senior Partner
Hirschler, Fleisher, Weinberg,
Cox and Allen, PC
31
Corporate Information
Corporate Offices and Lab Patent Counsel
Commonwealth Biotechnologies, Inc. Burns Doan Swecker and Mathis, LLP
601 Biotech Drive 1737 King Street
Richmond, VA 23235 Alexandria, VA 22314
Telephone: 800-735-9224; 804-648-3820 Transfer Agent and Registrar
Fax: 804-648-2641
E-mail: info@cbi-biotech.com Computershare Trust Company, Inc.
Web site: www.cbi-biotech.com 938 Quail Street, Suite 101
Denver, CO
Drug Development Division
Independent Auditors
Commonwealth Biotechnologies, Inc.
8110 Gatehouse Road, Suite 600-W McGladrey and Pullen, LLP
Falls Church, VA 22042 1051 East Cary Street
Richmond, VA 23226
General Counsel
LeClair Ryan,
A Professional Corporation
707 East Main Street, 11th Floor
Richmond, VA 23219
32